These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 22463933)

  • 1. What changes in inflammatory bowel disease management can be implemented today?
    Louis E; Baumgart DC; Ghosh S; Gomollón F; Hanauer S; Hart A; Irving P
    J Crohns Colitis; 2012 Feb; 6 Suppl 2():S260-7. PubMed ID: 22463933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EHealth: self-management in inflammatory bowel disease and in irritable bowel syndrome using novel constant-care web applications. EHealth by constant-care in IBD and IBS.
    Pedersen N
    Dan Med J; 2015 Dec; 62(12):B5168. PubMed ID: 26621403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improving quality of care in inflammatory bowel disease: what changes can be made today?
    Panés J; O'Connor M; Peyrin-Biroulet L; Irving P; Petersson J; Colombel JF
    J Crohns Colitis; 2014 Sep; 8(9):919-26. PubMed ID: 24713174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fecal markers: calprotectin and lactoferrin.
    Abraham BP; Kane S
    Gastroenterol Clin North Am; 2012 Jun; 41(2):483-95. PubMed ID: 22500530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fecal calprotectin in diagnosis and clinical assessment of inflammatory bowel disease.
    Sipponen T; Kolho KL
    Scand J Gastroenterol; 2015 Jan; 50(1):74-80. PubMed ID: 25523558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Faecal calprotectin in inflammatory bowel disease].
    Sipponen T; Kolho KL
    Duodecim; 2011; 127(24):2631-7. PubMed ID: 22320105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapid fecal calprotectin level assessment and the SIBDQ score can accurately detect active mucosal inflammation in IBD patients in clinical remission: a prospective study.
    Voiosu T; Benguş A; Dinu R; Voiosu AM; Bălănescu P; Băicuş C; Diculescu M; Voiosu R; Mateescu B
    J Gastrointestin Liver Dis; 2014 Sep; 23(3):273-8. PubMed ID: 25267955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Faecal calprotectin in inflammatory bowel diseases: review].
    Kallel L; Fekih M; Boubaker J; Filali A
    Tunis Med; 2011 May; 89(5):425-9. PubMed ID: 21557177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Faecal calprotectin assay after induction with anti-Tumour Necrosis Factor α agents in inflammatory bowel disease: Prediction of clinical response and mucosal healing at one year.
    Guidi L; Marzo M; Andrisani G; Felice C; Pugliese D; Mocci G; Nardone O; De Vitis I; Papa A; Rapaccini G; Forni F; Armuzzi A
    Dig Liver Dis; 2014 Nov; 46(11):974-9. PubMed ID: 25096964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in Use of Endoscopy, Radiology, and Biomarkers to Monitor Inflammatory Bowel Diseases.
    Panes J; Jairath V; Levesque BG
    Gastroenterology; 2017 Feb; 152(2):362-373.e3. PubMed ID: 27751880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New tools and approaches for improved management of inflammatory bowel diseases.
    Ghosh S; Pariente B; Mould DR; Schreiber S; Petersson J; Hommes D
    J Crohns Colitis; 2014 Oct; 8(10):1246-53. PubMed ID: 24742735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The long-term outcome of anti-tumor necrosis factor-α therapy related to fecal calprotectin values during induction therapy in pediatric inflammatory bowel disease.
    Kolho KL; Sipponen T
    Scand J Gastroenterol; 2014 Apr; 49(4):434-41. PubMed ID: 24597837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical utility of calprotectin and lactoferrin in patients with inflammatory bowel disease: is there something new from the literature?
    Caccaro R; D'Incà R; Pathak S; Sturniolo GC
    Expert Rev Clin Immunol; 2012 Aug; 8(6):579-85. PubMed ID: 22992152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inflammatory bowel disease.
    Mozdiak E; O'Malley J; Arasaradnam R
    BMJ; 2015 Sep; 351():h4416. PubMed ID: 26403642
    [No Abstract]   [Full Text] [Related]  

  • 15. Low fecal calprotectin predicts sustained clinical remission in inflammatory bowel disease patients: a plea for deep remission.
    Mooiweer E; Severs M; Schipper ME; Fidder HH; Siersema PD; Laheij RJ; Oldenburg B
    J Crohns Colitis; 2015 Jan; 9(1):50-5. PubMed ID: 25518048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management Strategies to Improve Outcomes of Patients With Inflammatory Bowel Diseases.
    Colombel JF; Narula N; Peyrin-Biroulet L
    Gastroenterology; 2017 Feb; 152(2):351-361.e5. PubMed ID: 27720840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Translating improved quality of care into an improved quality of life for patients with inflammatory bowel disease.
    Siegel CA; Allen JI; Melmed GY
    Clin Gastroenterol Hepatol; 2013 Aug; 11(8):908-12. PubMed ID: 23747710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Fecal calprotectin in the diagnosis of inflammatory bowel diseases].
    Rodríguez-Moranta F; Lobatón T; Rodríguez-Alonso L; Guardiola J
    Gastroenterol Hepatol; 2013; 36(6):400-6. PubMed ID: 23434080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T3 translational science in gastroenterology: getting to best outcomes.
    Crandall W
    Clin Gastroenterol Hepatol; 2013 Dec; 11(12):1559-61. PubMed ID: 24107397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Indicators of inflammatory process in stool in diagnostics and monitoring of inflammatory bowel diseases].
    Iwańczak B; Iwańczak F
    Pol Merkur Lekarski; 2015 Dec; 39(234):389-92. PubMed ID: 26802694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.